NDAINTRAVENOUSSOLUTION
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
MULTRYS (trace elements injection 4) by Am Regent is polymerases, rna polymerases, alcohol dehydrogenase, and alkaline phosphatases. Approved for copper, manganese, selenium for parenteral nutrition and 3 more indications. First approved in 2020.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MULTRYS is an intravenous trace elements injection containing zinc, copper, manganese, and selenium for patients requiring parenteral nutrition when enteral nutrition is not possible or insufficient. The drug works by supplying essential micronutrients that act as cofactors and catalysts for critical metalloenzymes involved in protein synthesis, oxidative stress defense, and metabolic regulation.
Peak14.7 years to LOE
Product is at peak lifecycle stage with robust patent protection through 2041, suggesting stable commercial operations but limited growth runway for expanding teams.
Mechanism of Action
polymerases, RNA polymerases, alcohol dehydrogenase, and alkaline phosphatases. Zinc is a coordinator of protein structural folding that interacts with a variety of proteins, lipids, and nucleic acids. In addition, zinc is a catalyst of essential biochemical reactions, including activation of…
Indications (6)
Worked on MULTRYS at Am Regent? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.